Sagimet Biosciences Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SGMT research report →
Range $7 – $29
Price Chart
About the company
Sagimet Biosciences Inc. , a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
- CEO
- David Happel
- IPO
- 2023
- Employees
- 16
- HQ
- San Mateo, CA, US
Get TickerSpark's AI analysis on SGMT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $648.02M
- P/E
- -7.63
- Fwd P/E
- 22.63
- PEG
- -0.18
- P/S
- 0.00
- P/B
- 2.34
- EV/EBITDA
- -9.64
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -29.95%
- ROIC
- -24.51%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-56,889,000
- Net Income
- $-51,038,000-12.0%
- EPS
- $-1.58-9.0%
- OCF Growth
- -7.6%
- FCF Growth
- -7.6%
- 52W High
- $11.45
- 52W Low
- $4.50
- 50D MA
- $9.80
- 200D MA
- $7.78
- Beta
- 3.47
- RSI (14)
- 47
- Avg Volume
- 1.23M
No earnings-call transcripts are available for SGMT yet.
- Free Float
- 83.9%
- Shares Outstanding
- 71.37M
- Float Shares
- 59.90M
of shares held by institutions
130 13F filers
Buy/sell ratio 0.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 6.97M | ▲ 394.42K |
| Balyasny Asset Management L.P. | 5.54M | ▲ 1.92M |
| Silverarc Capital Management, LLC | 3.75M | ▲ 818.29K |
| Bvf Inc/Il | 3.50M | ▲ 1.00M |
| Woodline Partners LP | 3.14M | ▲ 143.30K |
| Federated Hermes, Inc. | 3.09M | ▲ 1.01M |
| Caligan Partners LP | 2.79M | ▲ 294.48K |
| Commodore Capital LP | 2.76M | ▲ 2.76M |
| Vanguard Capital Management LLC | 2.63M | ▲ 60.28K |
| Affinity Asset Advisors, LLC | 2.53M | ▲ 29.52K |
| State Street Corp | 2.43M | ▲ 432.75K |
| Saturn V Capital Management LP | 2.00M | ▲ 522.89K |
Held by 160 ETFs
Biggest fund positions in SGMT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 14, 26 | Kemble George | other | 24,369 |
| Aug 14, 26 | Kemble George | other | 326,618 |
| Aug 14, 26 | Kemble George | sell | 350,987 |
| Aug 14, 26 | Kemble George | other | 326,618 |
| Aug 14, 26 | Kemble George | other | 24,369 |
| Aug 11, 26 | Kemble George | other | 9,751 |
| Aug 11, 26 | Kemble George | other | 10,455 |
| Aug 11, 26 | Kemble George | other | 9,751 |
| Aug 11, 26 | Kemble George | sell | 20,206 |
| Aug 11, 26 | Kemble George | other | 10,455 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SGMT coverage
Recent articles, reports, and earnings notes.
No research on SGMT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SGMT report →Sagimet: New Acne Medication In 40 Years (Initiating With A Buy)
seekingalpha.com · Nov 19
Sagimet Biosciences Inc. (NASDAQ:SGMT) Stock Has Average Price Target of $26.07
defenseworld.net · Nov 17
ACT Capital Partners L.P. Makes New $593,000 Investment in Sagimet Biosciences Inc. $SGMT
defenseworld.net · Nov 15
Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
globenewswire.com · Nov 12
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Oct 29
Wall Street Analysts Think Sagimet Biosciences Inc. (SGMT) Could Surge 168.24%: Read This Before Placing a Bet
zacks.com · Oct 23
Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne
globenewswire.com · Oct 22
Sagimet Biosciences: The U.S. Acne Trial Is A Replication Exercise, Not A Discovery Bet
seekingalpha.com · Oct 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.